Whitehawk Therapeutics Welcomes Dr. Vijay Iyengar to Its Board of Directors

Whitehawk Therapeutics Appoints Dr. Vijay Iyengar

Whitehawk Therapeutics, Inc. recently made a significant advancement in its corporate governance by adding Dr. Vijay Iyengar, MD, to its Board of Directors, effective September 9, 2026. This appointment comes at a crucial moment in the company's journey as it strives to make substantial progress in the field of oncology therapeutics.

Dr. Iyengar brings with him an impressive wealth of experience in oncology, having dedicated over two decades to building and scaling global businesses. He has a proven track record in orchestrating strategic transactions and guiding product portfolios from initial development stages to successful commercialization. Notably, during his nine-year tenure in senior leadership roles at Incyte Corporation, Dr. Iyengar was instrumental in the launch of five brands spanning eight indications. His efforts contributed significantly to the company's expansion into over 20 countries, witnessing a remarkable increase in annual revenue from approximately $1 billion to over $4 billion.

In welcoming Dr. Iyengar to the Board, Dave Lennon, the President and CEO of Whitehawk Therapeutics, expressed confidence in the value his expansive leadership experience in oncology would bring at this pivotal stage of the company’s growth. Lennon noted, "His extensive expertise will be invaluable as we continue to advance our clinical programs, expand our antibody-drug conjugate (ADC) portfolio, and make informed decisions to develop our promising pipeline."

Before his impactful role at Incyte, Dr. Iyengar held senior leadership positions in oncology at Novartis. He began his career as an Engagement Manager at McKinsey & Company, specializing in the healthcare sector. His academic accomplishments include a Bachelor of Science degree in Biology from Stanford University and a Doctor of Medicine from Harvard Medical School.

Sharing his thoughts on his new role, Dr. Iyengar highlighted his attraction to Whitehawk’s robust foundation rooted in scientific rigor and a clear strategic vision. He expressed enthusiasm in collaborating with the leadership team and fellow Board members to steer Whitehawk into its next growth phase as they work diligently to introduce innovative ADC treatments for cancer patients.

Whitehawk Therapeutics is currently at the cutting edge of cancer treatment, leveraging advanced technologies to improve established tumor biology, streamlining the development of enhanced ADC treatments. Their product lineup includes HWK-007, HWK-016, and HWK-206—engineered ADCs designed to surpass first-generation counterparts and deliver significant benefits to patients battling challenging cancers. These assets have been received through an exclusive development and global commercialization agreement with WuXi Biologics.

The company's innovative ADC platform incorporates CPT113 as the core linker-payload technology, enhanced by the proprietary Carbon Bridge Cysteine Re-pairing (CBCR) bioconjugation process, which contributes to improved stability and therapeutic efficacy. Furthermore, Whitehawk has an option agreement with Hangzhou DAC that grants access to CPT113 for utilization in up to five additional ADC programs.

As Whitehawk Therapeutics seeks to expand its offerings and pipeline opportunities, the company continues to focus on its commitment to enhancing patient outcomes through innovative therapies. For more information, visit their official website or connect on LinkedIn.

In summary, the appointment of Dr. Vijay Iyengar is not just a key addition to Whitehawk's Board; it signifies an exciting chapter for the company in its mission to revolutionize cancer treatment using advanced therapeutic techniques.